Functional state of specific immunity in children and teenagers vaccinated against mumps


Cite item

Full Text

Abstract

The functional state of immunity was evaluated from the avidity index (AI) of specific antibodies (IgG) and the level and spectrum of their neutralizing activity. The study recruited 200 subjects immunized with Russian vaccine against mumps according to the mandatory scheme. A group of vaccinees with a low AI of specific IgG was identified mainly among old children and teenagers. The vaccinees with a low AI had a significantly lower protective immunity (as shown from the level and spectrum of serum neutralizing activity) than those with a high AI. The vacinees with no humoral, incomplete, or complete postvaccination immunity, but with a low AI of specific IgG, can constitute a population stratum that preserves sensitivity to wild-type mumps viruses and serves as a favorable medium for their circulation.

References

  1. Зверев В. В., Юминова Н. В. Проблемы кори, краснухи и эпидемического паротита в Российской Федерации // Вопр. вирусол. - 2004. - № 3. - С. 8-11.
  2. Попов В. Ф., Каплунова О. П., Юнасова Т. Н. К вопросу о качестве и эффективности отечественной живой паротитной вакцины // Журн. эпидемиол. и иммунобиол. - 1997. - № 2. - С. 51-53.
  3. Atrasheuskaya A. V., Kulak M. V., Rubin S., Ignatyev G. M. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004 // Clin. Microbiol. Infect. - 2007. - Vol. 13. - P. 670-676.
  4. Atrasheuskaya A. V., Neverov A. A., Rubin S. V., Ignatyev G. M. Horizontal transmission of the L-3 live attenuated mumps vaccine virus // Vaccine. - 2006. - Vol. 24. - P. 1530-1536.
  5. Briss P. A., Fehrs L. J., Parker R. A. et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity // J. Infect. Dis. - 1004. - Vol. 169. - P. 77-82.
  6. Date A. A., Kyaw M. H., Rue A. M. et al. Long-term persistence of mumps antibody after receipt of 2 MMR vaccinations and antibody response after a third MMR vaccination among a university population // J. Infect. Dis. - 2008. - Vol. 197. - P. 1662-1668.
  7. Davidkin I., Jokinen S., Broman M. et al. Persistence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow up // J. Infect. Dis. - 2008. - Vol. 197. - P. 950-956.
  8. Dayan G. H., Rubin S. Mumps outbreaks in vaccinated populations; are available mumps vaccine effective enough to prevent outbreaks? // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 1458- 1467.
  9. Hanna-Wakim R., Yasukawa L. L., Sung P. P. et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood // J. Infect. Dis. - 2008. - Vol. 197. - P. 1667- 1675.
  10. Hersh B. S., Fine P. E. M., Kent W. et al. Mumps outbreak in a highly vaccinated population // J. Pediatr. - 1991. - Vol. 119. - P. 187-193.
  11. Jokinen S., Osterlund P., Julkunen I., Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumpls-rubella vaccination // J. Infect. Dis. - 2007. - Vol. 196. - P. 861-867.
  12. Kibinyiova M., Benes C., Prikazsky V. et al. Mumps vaccination in the Czech Republic // Eurosurveillance. - 2008. - Vol. 13. - P. 1-2.
  13. Narita M., Matsuzono Y., Takekoshi Y. et al. Analysis of mumps vaccine failure by means of avidity testing for mumpls virus-specific immunoglobulin G // Clin. Diagn. Lab. Immunol. - 1998. - Vol. 5. - P. 799-803.
  14. Nöjd J., Tecle T., Samuelsson A., Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype // Vaccine. - 2001. - Vol. 19. - P. 1727-1731.
  15. Norman G. R., Streiner D. L. Biostatistics. The Bare essential. - 2-nd Ed. - London, 2000. - P. 324.
  16. Paunio M., Hedman K., Davidkin I., Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy // Expert. Opin. Pharmacother. - 2003. - Vol. 4. - P. 1215-1225.
  17. Pebody R. G., Gay N. J., Hesketh L. M. et al. Immunogenecity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance // Vaccine. - 2002. - Vol. 15. - P. 1134-1140.
  18. Peltola H., Kulkarni P. S., Kapre S. V. et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines // Clin. Infect. Dis. - 2007. - Vol. 45. - P. 459-466.
  19. Rubin S., Mauldin J., Chumakov K. et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains // Vaccine. - 2006. - Vol. 24. - P. 2662-2668.
  20. Sanz-Moreno J. C., Limia-Sanchez A., Garcia-Comas L. et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G // Vaccine. - 2005. - Vol. 23. - P. 4921-4925.
  21. WHO-recommended standards for surveillance of selected vaccine-preventable diseases // Vaccines and Biologicals. - WHO. - Geneva, 2003. - P. 18-21.
  22. Yates P. J., Afzal M. A., Minor P. D. Antigenic and genetic variation of the NH protein of mumps virus strains // J. Gen. Virol. - 1996. - Vol. 77. - P. 2491-2497.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Otrashevskaya E.V., Bukin E.K., Krasil'nikov I.V., Ignat'ev G.M., Atrasheuskaya A.V., Bukin E.K., Krasilnikov I.V., Ignatyev G.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies